Swedish Orphan Biovitrum AB Stock Xetra
Equities
B6E
SE0000872095
Pharmaceuticals
Sales 2024 * | 25.12B 2.37B 2.18B 3.24B | Sales 2025 * | 27.21B 2.57B 2.36B 3.51B | Capitalization | 95.22B 8.99B 8.25B 12.3B |
---|---|---|---|---|---|
Net income 2024 * | 4.02B 379M 348M 519M | Net income 2025 * | 4.95B 467M 429M 639M | EV / Sales 2024 * | 4.32 x |
Net Debt 2024 * | 13.36B 1.26B 1.16B 1.73B | Net Debt 2025 * | 8.81B 832M 764M 1.14B | EV / Sales 2025 * | 3.82 x |
P/E ratio 2024 * |
22.3
x | P/E ratio 2025 * |
19
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 50.9% |
Latest transcript on Swedish Orphan Biovitrum AB
Managers | Title | Age | Since |
---|---|---|---|
Guido Oelkers
CEO | Chief Executive Officer | 59 | 17-05-21 |
Henrik Stenqvist
DFI | Director of Finance/CFO | 57 | 18-07-19 |
Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 68 | 20-12-31 | |
Annette Clancy
CHM | Chairman | 70 | 14-05-07 |
Staffan Schüberg
BRD | Director/Board Member | 55 | 19-12-31 |
1st Jan change | Capi. | |
---|---|---|
+7.40% | 101B | |
+8.42% | 42.18B | |
-13.04% | 32.26B | |
+80.80% | 29.79B | |
-10.92% | 16.06B | |
+1.93% | 14.45B | |
-6.77% | 12.01B | |
+177.16% | 10.71B | |
-56.13% | 8.83B |